Customer Support

Thank you for your interest
in AptoDetect™-Lung.


You can consult medical professionals in hospitals and medical centers using AptoDetect™-Lung.

① Patients with indeterminate nodules and in need of further examination
② Current smokers
③ Individuals with a family history of cancer

Total 7 types of biomarkers (EGFR1, MMP7, CA6, KIT, CRP, C9, and SERPINA3) in blood are measured.

The test result is shown as an index number between 0 to 10. The index 5 or above is high risk and the index below 5 is low risk.

Compared to LDCT, it is more convenient without the risk of radiation exposure. When used together with LDCT, it lowers the false positive rate and improves the diagnostic accuracy (complementary test). Furthermore, it is used as an in-depth test for the patients with the indeterminate nodule before the biopsy (confirmative complementary test) and for the patients after surgery who need follow-up care and regular check-ups to watch for recurrence (monitoring test).

The clinical effectiveness was confirmed in the first clinical test with Americans, and two more clinical trials in S. Korea have been conducted in total 600 patients. In the first clinical trial with 200 patients, 7 types of markers were selected, then in the next clinical trial, confirmative clinical trial has been conducted. Through the clinical validation and its evidence, AptoDetectTM-Lung is registered under MFDS (also known as KFDA).

The test result is risk index processed from 7 lung cancer-related biomarkers; thus it shows better diagnostic accuracy than the single biomarker. It also uses blood, so it is convenient and fast.